|
February 1, 2007
By:
Ben Bonifant, Michael Dombeck, Alex Lugovoy
Goodbye, M&As. Hello, L&As. The new trend in business development is licensing deals and acquisitions. The hot categories are CNS, oncology, and immunology. Now let's get bizzy.
|
September 1, 2006
By:
Nick Rogerson, Andrea Lauber
Roche, Johnson & Johnson, and Teva have demonstrated formidable deal making for many years. But generally, business development capabilities in the pharma industry remain very patchy, with the number of poor performers far out-weighing the good.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
